208 related articles for article (PubMed ID: 31871216)
1. Fluorouracil sensitivity in a head and neck squamous cell carcinoma with a somatic
Majounie E; Wee K; Williamson LM; Jones MR; Pleasance E; Lim HJ; Ho C; Renouf DJ; Yip S; Jones SJM; Marra MA; Laskin J
Cold Spring Harb Mol Case Stud; 2020 Feb; 6(1):. PubMed ID: 31871216
[TBL] [Abstract][Full Text] [Related]
2. Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment.
Amstutz U; Farese S; Aebi S; Largiadèr CR
Pharmacogenomics; 2009 Jun; 10(6):931-44. PubMed ID: 19530960
[TBL] [Abstract][Full Text] [Related]
3. Thymidylate synthase (TYMS) and dihydropyrimidine dehydrogenase (DPYD) polymorphisms in the Korean population for prediction of 5-fluorouracil-associated toxicity.
Cho HJ; Park YS; Kang WK; Kim JW; Lee SY
Ther Drug Monit; 2007 Apr; 29(2):190-6. PubMed ID: 17417073
[TBL] [Abstract][Full Text] [Related]
4. Hypermethylation of the DPYD promoter region is not a major predictor of severe toxicity in 5-fluorouracil based chemotherapy.
Amstutz U; Farese S; Aebi S; Largiadèr CR
J Exp Clin Cancer Res; 2008 Oct; 27(1):54. PubMed ID: 18937829
[TBL] [Abstract][Full Text] [Related]
5. Phenotypic profiling of DPYD variations relevant to 5-fluorouracil sensitivity using real-time cellular analysis and in vitro measurement of enzyme activity.
Offer SM; Wegner NJ; Fossum C; Wang K; Diasio RB
Cancer Res; 2013 Mar; 73(6):1958-68. PubMed ID: 23328581
[TBL] [Abstract][Full Text] [Related]
6. The role of dihydropyrimidine dehydrogenase expression in resistance to 5-fluorouracil in head and neck squamous cell carcinoma cells.
Yasumatsu R; Nakashima T; Uryu H; Masuda M; Hirakawa N; Shiratsuchi H; Tomita K; Fukushima M; Komune S
Oral Oncol; 2009 Feb; 45(2):141-7. PubMed ID: 18620897
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-494 sensitizes colon cancer cells to fluorouracil through regulation of DPYD.
Chai J; Dong W; Xie C; Wang L; Han DL; Wang S; Guo HL; Zhang ZL
IUBMB Life; 2015 Mar; 67(3):191-201. PubMed ID: 25873402
[TBL] [Abstract][Full Text] [Related]
8. DPYD*5 gene mutation contributes to the reduced DPYD enzyme activity and chemotherapeutic toxicity of 5-FU: results from genotyping study on 75 gastric carcinoma and colon carcinoma patients.
Zhang H; Li YM; Zhang H; Jin X
Med Oncol; 2007; 24(2):251-8. PubMed ID: 17848752
[TBL] [Abstract][Full Text] [Related]
9. Aberrant methylation of DPYD promoter, DPYD expression, and cellular sensitivity to 5-fluorouracil in cancer cells.
Noguchi T; Tanimoto K; Shimokuni T; Ukon K; Tsujimoto H; Fukushima M; Noguchi T; Kawahara K; Hiyama K; Nishiyama M
Clin Cancer Res; 2004 Oct; 10(20):7100-7. PubMed ID: 15501990
[TBL] [Abstract][Full Text] [Related]
10. Strong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-related toxicity in cancer patients.
Gross E; Busse B; Riemenschneider M; Neubauer S; Seck K; Klein HG; Kiechle M; Lordick F; Meindl A
PLoS One; 2008; 3(12):e4003. PubMed ID: 19104657
[TBL] [Abstract][Full Text] [Related]
11. [Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks].
Loriot MA; Ciccolini J; Thomas F; Barin-Le-Guellec C; Royer B; Milano G; Picard N; Becquemont L; Verstuyft C; Narjoz C; Schmitt A; Bobin-Dubigeon C; Harle A; Paci A; Poinsignon V; Quaranta S; Evrard A; Hennart B; Broly F; Fonrose X; Lafay-Chebassier C; Wozny AS; Masskouri F; Boyer JC; Etienne-Grimaldi MC
Bull Cancer; 2018 Apr; 105(4):397-407. PubMed ID: 29486921
[TBL] [Abstract][Full Text] [Related]
12. Long noncoding RNA LINC00261 induces chemosensitization to 5-fluorouracil by mediating methylation-dependent repression of DPYD in human esophageal cancer.
Lin K; Jiang H; Zhuang SS; Qin YS; Qiu GD; She YQ; Zheng JT; Chen C; Fang L; Zhang SY
FASEB J; 2019 Feb; 33(2):1972-1988. PubMed ID: 30226808
[TBL] [Abstract][Full Text] [Related]
13. Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy: mutations in the DPD gene, and DPD inhibitory fluoropyrimidines.
Omura K
Int J Clin Oncol; 2003 Jun; 8(3):132-8. PubMed ID: 12851836
[TBL] [Abstract][Full Text] [Related]
14. Two cases of 5-fluorouracil toxicity linked with gene variants in the DPYD gene.
Ofverholm A; Arkblad E; Skrtic S; Albertsson P; Shubbar E; Enerbäck C
Clin Biochem; 2010 Feb; 43(3):331-4. PubMed ID: 19822137
[TBL] [Abstract][Full Text] [Related]
15. Potential of dihydropyrimidine dehydrogenase genotypes in personalizing 5-fluorouracil therapy among colorectal cancer patients.
Teh LK; Hamzah S; Hashim H; Bannur Z; Zakaria ZA; Hasbullani Z; Shia JK; Fijeraid H; Md Nor A; Zailani M; Ramasamy P; Ngow H; Sood S; Salleh MZ
Ther Drug Monit; 2013 Oct; 35(5):624-30. PubMed ID: 23942539
[TBL] [Abstract][Full Text] [Related]
16. DPYD*2A and MTHFR C677T predict toxicity and efficacy, respectively, in patients on chemotherapy with 5-fluorouracil for colorectal cancer.
Nahid NA; Apu MNH; Islam MR; Shabnaz S; Chowdhury SM; Ahmed MU; Nahar Z; Islam MS; Islam MS; Hasnat A
Cancer Chemother Pharmacol; 2018 Jan; 81(1):119-129. PubMed ID: 29134491
[TBL] [Abstract][Full Text] [Related]
17. 5-Fluorouracil toxicity-attributable IVS14 + 1G > A mutation of the dihydropyrimidine dehydrogenase gene in Polish colorectal cancer patients.
Sulzyc-Bielicka V; Bińczak-Kuleta A; Pioch W; Kładny J; Gziut K; Bielicki D; Ciechanowicz A
Pharmacol Rep; 2008; 60(2):238-42. PubMed ID: 18443386
[TBL] [Abstract][Full Text] [Related]
18. Patients homozygous for DPYD c.1129-5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines.
Meulendijks D; Henricks LM; van Kuilenburg AB; Jacobs BA; Aliev A; Rozeman L; Meijer J; Beijnen JH; de Graaf H; Cats A; Schellens JH
Cancer Chemother Pharmacol; 2016 Oct; 78(4):875-80. PubMed ID: 27544765
[TBL] [Abstract][Full Text] [Related]
19. Absence of large intragenic rearrangements in the DPYD gene in a large cohort of colorectal cancer patients treated with 5-FU-based chemotherapy.
Paré L; Paez D; Salazar J; Del Rio E; Tizzano E; Marcuello E; Baiget M
Br J Clin Pharmacol; 2010 Aug; 70(2):268-72. PubMed ID: 20653680
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and safety of reduced-dose fluoropyrimidine therapy in patients carrying the DPYD*2A variant: A matched pair analysis.
Henricks LM; van Merendonk LN; Meulendijks D; Deenen MJ; Beijnen JH; de Boer A; Cats A; Schellens JHM
Int J Cancer; 2019 May; 144(9):2347-2354. PubMed ID: 30485432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
